Breast Journal 

About: Breast Journal is an academic journal published by Wiley-Blackwell. The journal publishes majorly in the area(s): Breast cancer & Cancer. It has an ISSN identifier of 1075-122X. Over the lifetime, 4061 publications have been published receiving 62712 citations.

Use of statistics to assess the global burden of breast cancer.

Abstract: A variety of statistics are used to quantify the burden (occurrence and outcome) of cancer generally and of breast cancer specifically. When undertaking any cancer control program, understanding these statistics, their source, and their quality is important for assessing the current situation, allocating resources to different control strategies, and evaluating progress. Two core statistics are the cancer incidence rate and the cancer mortality rate, which provide estimates of the average risk of acquiring and of dying from the disease, respectively. About 16% of the world's population is covered by registration systems that produce cancer incidence statistics, while mortality data are available for about 29%. Breast cancer incidence and mortality vary considerably by world region. In general, the incidence is high (greater than 80 per 100,000) in developed regions of the world and low (less than 30 per 100,000), though increasing, in developing regions; the range of mortality rates is much less (approximately 6–23 per 100,000) because of the more favorable survival of breast cancer in (high-incidence) developed regions. The incidence of breast cancer is increasing almost everywhere. This unfavorable trend is due in part to increases in risk factors (decreased childbearing and breast-feeding, increased exogenous hormone exposure, and detrimental dietary and lifestyle changes, including obesity and less physical activity). On the other hand, mortality is now decreasing in many high-risk countries due to a combination of intensified early detection efforts and the introduction of mammographic screening, resulting in the diagnosis of more small, early stage tumors, and advances in treatment.

Sentinel‐Node Biopsy to Avoid Axillary Dissection in Breast Cancer with Clinically Negative Lymph‐Nodes

Abstract: Background Axillary lymph-node dissection is an important staging procedure in the surgical treatment of breast cancer However, early diagnosis has led to increasing numbers of dissections in which axillary nodes are free of disease This raises first, questions about the need for the procedure We carried out a study to assess, first, whether a single axillary lymph node (sentinel node) initially receives malignant cells from a breast carcinoma and, second, whether a clear sentinel node reliably forecasts a disease-free axilla Methods In a consecutive series of 163 women with operable breast carcinoma, we injected microcolloidal particles of human serum albumin labelled with technetium-99m This tracer was injected subdermally, close to the tumor site, on the day before surgery, and scintigraphic images of the axilla and breast were taken 10 min, 30 min, and 3 h later A mark was placed on the skin over the site of the radioactive node (sentinel node) During breast surgery, a hand-held γ-ray det$ector probe was used to locate the sentinel node, and make possible its separate removal via a small axillary incision Complete axillary lymphadenectomy was then done The sentinel node was tagged separately from other nodes Permanent sections of all removed nodes were prepared for pathological examination Findings From the sentinel node, we could accurately predict axillary lymph-node status in 156 (975%) of the 160 patients in whom a sentinel node was identified, and in all cases (45 patients) with tumours less than 15 cm in diameter In 32 (38%) of the 85 cases with metastatic axillary nodes, the only positive node was the sentinel node Interpretation In the large majority of patients with breast cancer, lymphoscintigraphy and γ-probe-guided surgery can be used to locate the sentinel node in the axilla, and thereby provide important information about the status of axillary nodes Patients without clinical involvement of the axilla should undergo sentinel-node biopsy routinely, and may be spared complete axillary dissection when the sentinel node is disease-free

Breast cancer in Iran: an epidemiological review.

Abstract: Breast cancer is one of the most frequent malignancies among Iranian women, however; the epidemiological aspects of breast cancer among Iranian patients are uncertain. A literature review of the published articles from January 1998 to December 2005 was conducted using different search engines: MEDLINE, Scientific information data base of Academic Center for Education, Culture and Research, and over 2000 issues of 94 Persian medical journals. The headings "Breast Cancer,""Breast Tumor,""Breast Malignancy," and "Breast Carcinoma" were combined with the word "Iran" to execute the search. In all, 85 full papers were reviewed. These findings showed that participants ranged from 15 to 84 years old, with those 40-49 being the most prevalent. The incidence of breast cancer in women was 22 per 100,000. The prevalence in this same population was 120 per 100,000. Stage I was diagnosed in 18%, stage II in 57% and stage III in 25% of the cases. About 72% of the patients were diagnosed with a tumor over 2 cm. Sixty-three percent of the patients had lymph node involvement at the diagnostic time. Infiltrative ductal carcinoma was found to be the most common at 77% and lobular carcinoma the least at 5%. This review indicates that the epidemiological aspects of breast cancer in Iran are relatively well-studied. Shortcomings in study of its clinical aspects are evident and need to be a central part of upcoming investigations.

Breast Cancer in Limited‐Resource Countries: An Overview of the Breast Health Global Initiative 2005 Guidelines

Abstract: � Abstract: Breast cancer is the most common cause of cancer-related death among women worldwide, with case fatality rates highest in low-resource countries. Despite significant scientific advances in its management, most of the world faces resource constraints that limit the capacity to improve early detection, diagnosis, and treatment of the disease. The Breast Health Global Initiative (BHGI) strives to develop evidence-based, economically feasible, and culturally appropriate guidelines that can be used in nations with limited health care resources to improve breast cancer outcomes. Using an evidence-based consensus panel process, four BHGI expert panels addressed the areas of early detection and access to care, diagnosis and pathology, treatment and resource allocation, and health care systems and public policy as they relate to breast health care in limited-resource settings. To update and expand on the BHGI Guidelines published in 2003, the 2005 BHGI panels outlined a stepwise, systematic approach to health care improvement using a tiered system of resource allotment into four levels—basic, limited, enhanced, and maximal— based on the contribution of each resource toward improving clinical outcomes. Early breast cancer detection improves outcome in a cost-effective fashion assuming treatment is available, but requires public education to foster active patient participation in diagnosis and treatment. Clinical breast examination combined with diagnostic breast imaging (ultrasound ± diagnostic mammography) can facilitate cost-effective tissue sampling techniques for cytologic or histologic diagnosis. Breast-conserving treatment with partial mastectomy and radiation therapy requires more health care resources and infrastructure than mastectomy, but can be provided in a thoughtfully designed limited-resource setting. The availability and administration of systemic therapies are critical to improving breast cancer survival. Estrogen receptor testing allows patient selection for hormonal treatments (tamoxifen, oophorectomy). Chemotherapy, which requires some allocation of resources and infrastructure, is needed to treat node-positive, locally advanced breast cancers, which represent the most common clinical presentation of disease in low-resource countries. When chemotherapy is not available, patients with locally advanced, hormone receptor-negative cancers can only receive palliative therapy. Future research is needed to better determine how these guidelines can best be implemented in limited-resource settings. �

Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study.

Abstract: There are many conflicting results in the literature comparing quality of life following breast-conserving therapy (BCT) and mastectomy. This study compared long-term quality of life between breast cancer patients treated by BCT or mastectomy in three age groups. Patients (n = 990) completed a quality of life survey, including the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), at regular intervals over 5 years. In the cross-sectional data, mastectomy patients had significantly (p or =70 years of age reported higher body image and lifestyle scores when treated with BCT. The repeated measures analysis indicated that four functioning scores, half the symptom scores, future health, and global quality of life improved significantly (p < 0.01) over time. All these variables increased significantly for BCT patients and those 50 to 69 years of age. Body image, sexual functioning, and lifestyle disruption scores did not improve over time. BCT should be encouraged in all age groups. Coping with appearance change should be addressed in patient interventions.